EMulate Therapeutics Announces the Incorporation of a Third Wholly Owned Subsidiary
Back to Newsroom

EMulate Therapeutics Announces the Incorporation of a Third Wholly Owned Subsidiary

Wednesday, February 23, 2022 1:05 PM

EMulate Therapeutics Has Incorporated A New Wholly Owned Subsidiary to Deploy Its Platform Technology for the Treatment of Cancer.

BELLEVUE, WA / ACCESSWIRE / February 23, 2022 / EMulate Therapeutics, Inc., a clinical-stage therapeutic device company focused on developing and commercializing innovative and distinctive therapies to address critical unmet needs in healthcare, today announced the incorporation of a third wholly owned subsidiary, Cellsana Therapeutics, Inc. Last year, EMulate incorporated Indolor Therapeutics, Inc. to focus on therapies for those suffering from serious pain conditions and Mensana Therapeutics, Inc. to focus on therapies for those suffering from a variety of mental health conditions. Through Cellsana Therapeutics, Inc., EMulate will use its proprietary radio frequency energy (RFE) technology, targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®), to provide safe and effective therapies to those suffering from cancer. (See www.emulatetx.com; News, for recent press releases.)

"We are extremely pleased to establish this third new subsidiary company, yet another step in successfully executing our long-term business strategy," said Chris Rivera, President and Chief Executive Officer of EMulate Therapeutics, Inc. "The initial focus for Cellsana will be to initiate the Phase III, pivotal registration study in diffuse midline gliomas, a rare, but extremely aggressive and terminal brain cancer primarily diagnosed in children. In addition, Cellsana will begin planning for the initiation of our pivotal registration trial for patients with newly diagnosed glioblastoma. Feasibility clinical trial results for both of these indications were extremely encouraging, we are excited to initiate both studies. Further, Cellsana will initiate pre-clinical work for additional solid tumor indications that can lead to human clinical studies."

EMulate's business strategy is to leverage its proprietary ulRFE technology into multiple subsidiary vertical business units that can be partnered or built into successful independent commercial companies, as the company did with Hapbee Technologies, Inc. (HAPB:TVXS), a publicly traded, commercial, consumer wearable technology company. EMulate is currently seeking or is in discussions with multiple potential long-term strategic investors and/or licensing partners.

About EMulate Therapeutics, Inc.

EMulate Therapeutics is a clinical stage company utilizing its proprietary radio frequency energy technology (RFE) targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®) to provide safe and effective therapeutic benefits specifically targeted at the patients' underlying conditions. The company has generated encouraging human data from patients afflicted with glioblastoma and diffuse midline glioma and is preparing for pivotal (phase III) studies in each indication. It has also generated encouraging preclinical data in pain management and mental health models and is preparing for initial human clinical trials in each area. In addition, positive data have been generated independently in animal health and bio-agriculture models. EMulate Therapeutics is the licensor of its proprietary technology to Hapbee Technologies, Inc. (HAPB: TSVX). Hapbee is a commercial stage consumer technology company spun out from EMulate in 2019. EMulate is the largest independent shareholder in Hapbee and recipient of quarterly royalties from net sales.

Company Contact:
David Matteson
[email protected]
Cell: 425/478-2121

Investor Contact
James Carbonara
Hayden IR
Tel (646) 755-7412
[email protected]

To learn more, please visit https://emulatetx.com/

SOURCE: EMulate Therapeutics, Inc.

Topic:
Company Update
Back to newsroom
Back to Newsroom